CN102335272B - Liquid preparation for diminishing inflammation and preparation method thereof - Google Patents
Liquid preparation for diminishing inflammation and preparation method thereof Download PDFInfo
- Publication number
- CN102335272B CN102335272B CN 201110302145 CN201110302145A CN102335272B CN 102335272 B CN102335272 B CN 102335272B CN 201110302145 CN201110302145 CN 201110302145 CN 201110302145 A CN201110302145 A CN 201110302145A CN 102335272 B CN102335272 B CN 102335272B
- Authority
- CN
- China
- Prior art keywords
- preparation
- boiled
- weight
- herba
- cooled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 60
- 239000007788 liquid Substances 0.000 title abstract description 26
- 206010061218 Inflammation Diseases 0.000 title abstract description 25
- 230000004054 inflammatory process Effects 0.000 title abstract description 11
- 230000003467 diminishing effect Effects 0.000 title abstract 6
- 239000003814 drug Substances 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 239000006188 syrup Substances 0.000 claims abstract description 27
- 235000020357 syrup Nutrition 0.000 claims abstract description 27
- 229930006000 Sucrose Natural products 0.000 claims abstract description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 15
- 239000005720 sucrose Substances 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 230000002421 anti-septic effect Effects 0.000 claims description 17
- 238000012856 packing Methods 0.000 claims description 15
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 14
- 238000001816 cooling Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 11
- 239000012567 medical material Substances 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 235000013355 food flavoring agent Nutrition 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 6
- 239000012669 liquid formulation Substances 0.000 claims description 6
- 239000004302 potassium sorbate Substances 0.000 claims description 6
- 235000010241 potassium sorbate Nutrition 0.000 claims description 6
- 229940069338 potassium sorbate Drugs 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 4
- 239000004299 sodium benzoate Substances 0.000 claims description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims description 4
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 claims description 3
- BITWJFGNJJIOII-UHFFFAOYSA-N 2,3-dichloro-1,3-diphenylprop-2-en-1-one Chemical class ClC(=C(C1=CC=CC=C1)Cl)C(=O)C1=CC=CC=C1 BITWJFGNJJIOII-UHFFFAOYSA-N 0.000 claims description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 3
- 239000004377 Alitame Substances 0.000 claims description 3
- 239000004378 Glycyrrhizin Substances 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 3
- 229960004998 acesulfame potassium Drugs 0.000 claims description 3
- 239000000619 acesulfame-K Substances 0.000 claims description 3
- 235000019409 alitame Nutrition 0.000 claims description 3
- 108010009985 alitame Proteins 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229940109275 cyclamate Drugs 0.000 claims description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical group OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 3
- -1 erithritol Chemical compound 0.000 claims description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 3
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000233839 Commelina communis Species 0.000 abstract 1
- 241000155182 Monochasma Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000006049 herbal material Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 10
- 238000009472 formulation Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 6
- 230000005484 gravity Effects 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000002741 palatine tonsil Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010044008 tonsillitis Diseases 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010020741 Hyperpyrexia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010001093 acute tonsillitis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- SJUWEPZBTXEUMU-LDXVYITESA-N 7-bromo-6-chloro-3-[3-[(2s,3r)-3-hydroxypiperidin-2-yl]-2-oxopropyl]quinazolin-4-one;hydrobromide Chemical compound Br.O[C@@H]1CCCN[C@H]1CC(=O)CN1C(=O)C2=CC(Cl)=C(Br)C=C2N=C1 SJUWEPZBTXEUMU-LDXVYITESA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010030094 Odynophagia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001165 anti-coccidial effect Effects 0.000 description 1
- 229930191701 arteannuin Natural products 0.000 description 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000017454 sodium diacetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese medicine for resisting bacteria and diminishing inflammation, and a liquid preparation for diminishing inflammation. A Chinese medicinal composition comprises the following Chinese herbal materials in part by weight: 1,500 to 1,568 parts of herb of savatier monochasma, 745 to 788 parts of commelina communis, and 745 to 788 parts of hedyotis diffusa. The liquid preparation for diminishing inflammation is an oral medicinal preparation which does not contain medicinal excipients or an oral medicinal preparation containing sucrose or sweetener, preferably the liquid preparation is oral liquid or syrup. The composition is a pure Chinese medicinal preparation; compared with the common antibiotic medicine, the composition has the advantages that the compositionhas small side effects and a human body does not have medicine resistance after taking the composition for a long time; the preparation for diminishing inflammation is the liquid preparation (the oral liquid or syrup); and compared with the common Chinese medicine for diminishing inflammation, the composition can be absorbed easily by a human body, has quick response, is easy to take and wide in an application range.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and Chinese medicine preparation, particularly relate to a kind of Chinese medicine composition for anti-inflammation and anti-inflammation formulation and preparation method thereof.
Background technology
Existing antibiotic medicine antibiotics is in the majority, and the antibiotics product is internal and international repeats injunctions, and bans use of, and this quasi drugs life-time service easily makes people's body immunity descend, and makes human body produce drug resistance, and is very big to the human injury.Pure Chinese medicinal preparation antibiotic medicine with antiinflammation all is oral solid formulations, as tablet, capsule and granule, the infiltration rate of this solid preparation of Chinese medicine and onset are all slower, and it is harmful and do not have profit to people's health to add certain adjuvant in the preparation process, and above-mentioned medicine all can not well be fit to clinical requirement.
Number of patent application is 200710092965.8 Chinese patent application, open day is 2008.4.30, " a kind of Laryngalgia anti-inflammation Chinese medicine preparation that improves taste and preparation method thereof " disclosed, it is the process modification that existing Chinese patent medicine Laryngalgia anti-inflammation ball is carried out, solved the lasting bitter to the taste numb tongue flavor that causes because of the Venenum Bufonis medical material, laryngalgia had certain alleviation and healing effect, but because said preparation preferred tablet form, infiltration rate is slower, the course for the treatment of is longer, and the adjuvant that contains non-Chinese medicine ingredients in this Chinese medicine preparation causes certain harm to people's cognition.
Number of patent application is 200810151354.0 Chinese patent application, open day is 2009.2.11, disclose " a kind of anticoccidial, hemostasis are enriched blood, anti-inflammation Chinese medicine composition and preparation method thereof ", its main component is arteannuin and halofuginone hydrobromide, this Chinese medicine preparation is granule, mainly is applicable to animal body.
Patent announcement number is the patent of CN1159043C, a kind of " dephlogisticate Chinese medicine oral liquid " disclosed, made by natural Chinese medicines such as Folium Isatidis, Fructus Forsythiae, Flos Lonicerae, Radix Bupleuri, has the effect of bringing down a fever with antiinflammatory, have no side effect, this Chinese medicine preparation is oral liquid, human body has absorption preferably, but this Chinese medicine oral liquid mainly is applicable to the hyperpyrexia that cold, fever causes, the effect of bringing down a fever obviously, for the inflammation that is caused by fever assist in treating is arranged, do not see that for the inflammation that other reasons causes the therapeutic effect of this respect verification experimental verification is arranged.
Summary of the invention
The pure Chinese medicine composition that the technical problem to be solved in the present invention provides a kind of taking convenience, is easy to absorption of human body, instant effect, antiinflammatory are effective, pure Chinese medicine anti-inflammation formulation and preparation method thereof.
For reaching above-mentioned purpose, anti-inflammatory medicine compositions of the present invention contains following parts by weight of Chinese traditional medicine raw material: Herba monochasmatis 1500-1568, Herba Commelinae 745-788, Herba Hedyotidis Diffusae 745-788.
Wherein the weight portion of each raw material of Chinese medicine is preferred: Herba monochasmatis 1550-1566, Herba Commelinae 750-785, Herba Hedyotidis Diffusae 750-785.More preferably: Herba monochasmatis 1562.5, Herba Commelinae 781.25, Herba Hedyotidis Diffusae 781.25.
The scorching peaceful liquid preparation of the present invention for not containing the oral drug preparation form of medicinal adjuvant, or contains the oral drug preparation form of sucrose or sweeting agent.Preferred described preparation is oral liquid or syrup.
The scorching peaceful liquid preparation of the present invention when its preparation is syrup, is divided into sugared type syrup and Sugarless type syrup is arranged, and it is 600-650 that the weight portion that sucrose adds in the sugared type syrup is arranged, and the weight portion that sweeting agent described in the Sugarless type syrup adds is 0.5-5.
The present invention prepares the method for the peaceful liquid preparation of above-mentioned inflammation, take by weighing each raw medicinal material respectively by proportioning described above, raw medicinal material is decocted with water twice, for the first time amount of water be medical material weight 6-15 doubly, for the second time amount of water be medical material weight 5-12 doubly, decocted 1.5 hours for the first time, decocted 1 hour for the second time, collecting decoction filters and discards medicinal residues, it is 1.0-1.10 (using the gravity Baume instrumentation for 80 ℃) that filtrate is concentrated into density, add ethanol, make to contain the alcohol amount in the filtrate to reach parts by weight be 50%-60%, stir, left standstill 10-14 hour, filter alcoholic solution, the ethanol in the filtrate is reclaimed, last solution is the aqueous solution that does not contain alcohol, it is 1.10-1.20 (using the gravity Baume instrumentation for 80 ℃) that the filtrate continuation of removing ethanol is concentrated into density, and it is standby to make extract;
Get the sucrose heating for dissolving of above-mentioned weight portion, add said extracted thing and antiseptic then, heated and boiled keeps little and boiled 20 minutes, is cooled to below 60 ℃, is settled to scale, continues to be cooled to 45-55 ℃, and packing has namely got sugared type syrup; Perhaps, get the said extracted thing and be heated to 55-65 ℃, add sweeting agent and the antiseptic heated and boiled of above-mentioned weight portion then, keep little and boiled 20 minutes, be cooled to below 60 ℃, be settled to scale, continue to be cooled to 45-55 ℃, packing namely gets the Sugarless type syrup; Perhaps, get the said extracted thing and add an amount of purified water heating dilution, add flavoring agent and antiseptic heated and boiled then, keep little and boiled 20 minutes, cooling is settled to scale below 60 ℃, continues to be cooled to 45-55 ℃, and packing namely gets oral liquid formulations.
The present invention prepares in the method for scorching peaceful liquid preparation, and used sweeting agent is cyclamate, steviosin, acesulfame potassium, sucralose, alitame, novel compound sweeting agent, protein sugar, xylitol, dichloro chalcone derivative, oligosaccharide, erithritol, glycyrrhizin, Fructus Momordicae extracting solution or thaumati etc.
The present invention prepares in the method for scorching peaceful liquid preparation, and used antiseptic is sodium benzoate or potassium sorbate, and addition accounts for 0.25% (mass volume ratio, namely the addition of antiseptic is 0.25g in the scorching peaceful preparation of every 100ml) of scorching peaceful preparation total amount.
The present invention prepares in the method for scorching peaceful liquid preparation, used flavoring agent is essence and citric acid, addition accounts for 0.03% (volume ratio of scorching peaceful preparation total amount respectively, be the essence that contains 0.03ml in the scorching peaceful preparation of 100ml) and 0.05% (mass volume ratio, namely the addition of citric acid is 0.05g in the scorching peaceful preparation of every 100ml).
The used raw medicinal material of the present invention all can be bought from common Chinese material shop and obtain, and its specification meets national Chinese crude drug standard and gets final product.Used sweeting agent, flavoring agent and the antiseptic of the present invention also can have been bought from the market, and it meets state food, the drug safety standard gets final product.
The application of Chinese medicine composition of the present invention in the preparation anti-inflammation drugs can be used for preparing inflammation medicines such as upper respiratory tract infection resistant, tonsillitis, urinary tract infection, acute bacillary dysentery and enteritis.
Anti-inflammatory medicine compositions difference from prior art of the present invention is that the present composition is pure Chinese medicinal preparation, compares with antibiotic medicine commonly used, and few side effects is taken for a long time and can not be made human body generation drug resistance; The peaceful preparation of preparation of the present invention-inflammation is liquid preparation (oral liquid or syrup), compares with Chinese medicine antibiotic medicine commonly used, is more conducive to absorption of human body, and is rapid-action, taking convenience, and it is wide to be suitable for the crowd, is specially adapted to old man and children taking.
To anti-inflammatory medicine compositions of the present invention, scorching peaceful liquid preparation and preparation method thereof is described further below in conjunction with specific embodiment.
The specific embodiment
Below in conjunction with embodiment and test data, be described in more detail with other technical characterictic and advantage the present invention is above-mentioned.
Embodiment 1
Take by weighing following raw material respectively:
Herba monochasmatis 1562.5g, Herba Commelinae 781.25g, Herba Hedyotidis Diffusae 781.25g, sucrose 650g, sweeting agent 2g.
Raw medicinal material is decocted with water twice, for the first time amount of water is 15 times of medical material weight, be that amount of water is 46.9kg, for the second time amount of water is 12 times of medical material weight, and namely amount of water is 37.5kg, decocts 1.5 hours for the first time, decocted 1 hour for the second time, collecting decoction filters and discards medicinal residues, and it is 1.10 (using the gravity Baume instrumentation for 80 ℃) that filtrate is concentrated into density, add ethanol, making the alcohol amount of containing in the filtrate reach parts by weight is 60%, stirs, and leaves standstill 12 hours, filter, reclaim the ethanol in the filtrate, it is 1.20 (using the gravity Baume instrumentation for 80 ℃) that the filtrate continuation that does not contain ethanol is concentrated into density, and it is standby to make extract;
Getting above-mentioned weight is the sucrose heating for dissolving of 650g, adds said extracted thing and sodium benzoate 2.5g then, and heated and boiled keeps little and boiled 20 minutes, and cooling is settled to 1000ml below 60 ℃, continues to be cooled to about 50 degree, and packing has namely got sugared type syrup.
Present embodiment also can make the Sugarless type syrup, getting the said extracted thing is heated to about 60 degree, sweeting agent and antiseptic 2.5g that to add above-mentioned load weighted weight then be 2g, heated and boiled, keep little and boiled 20 minutes, cooling is filtered and is settled to 1000ml below 60 ℃, continue to be cooled to about 50 degree, packing namely gets the Sugarless type syrup.
Present embodiment also can make the oral solutions that does not add sucrose and any sweeting agent, get the said extracted thing and add an amount of purified water, the addition of pure water is about 60% of the above-mentioned extract weight that makes, and the heating dilution adds 0.3ml essence, 0.5g citric acid and 2.5g sodium benzoate then, heated and boiled, keep little and boiled 20 minutes, cooling is filtered and is settled to 1000ml below 60 ℃, continue to be cooled to about 50 degree, packing namely gets oral liquid formulations.
Embodiment 2
Take by weighing following raw material respectively:
Herba monochasmatis 1500g, Herba Commelinae 745g, Herba Hedyotidis Diffusae 745g, sucrose 600g, sweeting agent 0.5g.
Raw medicinal material is decocted with water twice, for the first time amount of water is 6 times of medical material weight, be that amount of water is 17.9kg, for the second time amount of water is 5 times of medical material weight, and namely amount of water is 14.95kg, decocts 1.5 hours for the first time, decocted 1 hour for the second time, collecting decoction filters and discards medicinal residues, and it is 1.0 (using the gravity Baume instrumentation for 80 ℃) that filtrate is concentrated into density, add ethanol, making the alcohol amount of containing in the filtrate reach parts by weight is 50%, stirs, and leaves standstill 10 hours, filter, reclaim the ethanol in the filtrate, it is 1.10 (using the gravity Baume instrumentation for 80 ℃) that the filtrate continuation that does not contain ethanol is concentrated into density, and it is standby to make extract;
Getting above-mentioned weight is the sucrose heating for dissolving of 600g, adds said extracted thing and potassium sorbate 2.5g then, and heated and boiled keeps little and boiled 20 minutes, and cooling is filtered below 60 ℃, is settled to 1000ml, continues to be cooled to 45 ℃, and packing has namely got sugared type syrup.
Present embodiment also can make the Sugarless type syrup, get the said extracted thing and be heated to 55 ℃, sweeting agent and potassium sorbate 2.5g that to add above-mentioned load weighted weight then be 2g, heated and boiled, keep little and boiled 20 minutes, cooling is filtered below 60 ℃, is settled to 1000ml, continue to be cooled to 45 ℃, packing namely gets the Sugarless type syrup.
Present embodiment also can make the oral solutions that does not add sucrose and any sweeting agent, get the said extracted thing and add an amount of purified water, the addition of pure water is 60% of the above-mentioned extract weight that makes, and the heating dilution adds 0.3ml essence, 0.5g citric acid and 2.5g potassium sorbate then, heated and boiled, keep little and boiled 20 minutes, cooling is filtered below 60 ℃, is settled to 1000ml, continue to be cooled to 45 ℃, packing namely gets oral liquid formulations.
Embodiment 3
Take by weighing following raw material respectively:
Herba monochasmatis 1568g, Herba Commelinae 788g, Herba Hedyotidis Diffusae 788g, sucrose 630g, sweeting agent 3.0g.
Raw medicinal material is decocted with water twice, for the first time amount of water is 10 times of medical material weight, be that amount of water is 31.5kg, for the second time amount of water is 8 times of medical material weight, and namely amount of water is 25.2kg, decocts 1.5 hours for the first time, decocted 1 hour for the second time, collecting decoction filters and discards medicinal residues, and it is 1.15 that filtrate is concentrated into density, add ethanol, making the alcohol amount of containing in the filtrate reach parts by weight is 55%, stirs, and leaves standstill 14 hours, filter, reclaim the ethanol in the filtrate, it is 1.15 that the filtrate continuation that does not contain ethanol is concentrated into density, and it is standby to make extract;
Getting above-mentioned weight is the sucrose heating for dissolving of 630g, adds said extracted thing and 2.5g antiseptic then, and heated and boiled keeps little and boiled 20 minutes, and cooling is settled to 1000ml, continues to be cooled to 55 ℃, and packing has namely got sugared type syrup.
Present embodiment also can make the Sugarless type syrup, gets the said extracted thing and is heated to 65 ℃, sweeting agent and 2.5g antiseptic that to add above-mentioned load weighted weight then be 3g, heated and boiled keeps little and boiled 20 minutes, and cooling is settled to 1000ml, continue to be cooled to 55 ℃, packing namely gets the Sugarless type syrup.
Present embodiment also can make the oral solutions that does not add sucrose and any sweeting agent, get the said extracted thing and add an amount of purified water, the addition of pure water is 60% of the above-mentioned extract weight that makes, and the heating dilution adds 0.8g flavoring agent and 2.5g antiseptic then, heated and boiled, keep little and boiled 20 minutes, cooling is filtered below 60 ℃, is settled to 1000ml, continue to be cooled to 55 ℃, packing namely gets oral liquid formulations.
In other embodiments, can also take by weighing the raw material of Chinese medicine of following weight: Herba monochasmatis 1550g, Herba Commelinae 750g, Herba Hedyotidis Diffusae 750g or Herba monochasmatis 1566g, Herba Commelinae 785g, Herba Hedyotidis Diffusae 785g, described in the preparation method of anti-inflammation formulation such as the above-mentioned embodiment.
Used sweeting agent can be this areas such as cyclamate, stevioside, acesulfame potassium, sucralose, alitame, novel compound sweeting agent, protein sugar, xylitol, dichloro chalcone derivative, oligosaccharide, erithritol, glycyrrhizin, Fructus Momordicae extracting solution or thaumati sweeting agents commonly used in above-described embodiment.
Used antiseptic can also be this areas such as benzoic acid and salt, potassium sorbate, dehydro sodium acetate, propyl p-hydroxybenzoate, calcium propionate, sodium diacetate, sodium lactate, streptococcus acidi lactici, natamycin antiseptic commonly used in above-described embodiment.The addition of antiseptic is 0.25% of scorching peaceful total formulation weight amount.
Used flavoring agent can also be this areas such as citric acid, lactic acid, malic acid, flavoring pineapple essence flavoring agents commonly used in above-described embodiment.The interpolation total amount of flavoring agent is the 0.07-0.09% of scorching peaceful liquid preparation gross weight.
Test example 1: anti-inflammatory medicine compositions of the present invention is to tonsillitic therapeutic effect.
This test is divided into two groups: treatment group and matched group.
Case is selected: Western medicine diagnose is with reference to Ministry of Public Health regulation " Clinical Researches of New Drugs guideline ".Tcm diagnosis and dialectical standard are all formulated with reference to high hospital school teaching material " Chinese Internal Medicine " (five editions teaching materials) and " Clinical Researches of New Drugs guideline ".
214 routine acute tonsillitis patients are divided into two groups at random, treatment group 112 example and matched group 102 examples, two groups of patients' sex, age, antiadoncus degree distribution situation see Table 1.
Table 1 liang group sex, age, antiadoncus degree distribution situation
Use x
2Or the t check, two groups of patient's sexes, age and state of an illness distribution there was no significant differences (P＜0.05) have comparability.
The scorching peaceful preparation that the treatment group selects for use above-described embodiment to obtain, each 10ml, every day 3-4 time, one after each meal.Matched group adopts penicillin 800,000 intramuscular injection, every day 3 times.
Observation item and index: (1) main observed content: tonsillitic symptom comprises hyperpyrexia, pharyngalgia, odynophagia, submandibular lymph nodes enlargement etc.(2) inflammation classification: tonsillitis is divided into acute tonsillitis and chronic tonsillitis.(3) division of severity extent: slight: pharyngeal hypodynia, tonsil is little swollen, can take food but pain when taking food; Moderate: pharyngeal pain, congested antiadoncus can advance a small amount of liquid food, and there are point-like or lamellar purulent exudate in the tonsil surface; Severe: pharyngeal obvious congested pain, the serious enlargement of tonsil can not be taken food, and yellow lamellar secretions is arranged, easily wipe, and head, general pain are had a high fever, simultaneously with symptoms such as abdominal distention, constipation, short urination are red.
Efficacy assessment standard: formulate with reference to " new Chinese medicine clinical research guideline ".Clinic control: after the medication in 3 hours pharyngeal pain, hyperemia and antiadoncus obviously disappear, tonsil surface point-like or lamellar purulent exudate disappear, can take food the same day; Produce effects: after the medication in 6 hours antiadoncus obviously disappear, pharyngeal little pain or uncomfortable that has, can advance a small amount of liquid food the same day; Invalid: pharyngeal still pain, hyperemia in the medication 24 hours, can not take food.
The result: two groups of curative effects relatively see Table 2.
Two groups of curative effects of table 2 treatment group and matched group relatively
Invalid 2 examples were cured in two days in the treatment group, cure rate 100%; 51 examples that matched group is invalid continue medication and still had 36 examples to fail to cure cure rate 64.7% in 3 days.
Analyze with Radit, R (treatment group) R2 (matched group) illustrates that treatment group treatment tonsillitis effect is better than matched group, carries out the U of R value is checked that two groups of curative effects have significant difference (P＜0.05).
Test example 2, the scorching peaceful preparation of anti-inflammatory medicine preparation of compositions of the present invention is injected influence/x ± s that carrageenin causes inflammatory swelling, n=8 to rat paw.The results are shown in Table 3.
The scorching peaceful liquid preparation of table 3 anti-inflammatory medicine preparation of compositions of the present invention causes the influence of inflammatory swelling to rat paw injection carrageenin
Annotate: check, compare with the normal saline group,
* 1P＜0.05,
* 2P＜0.01,
* 3P＜0.001
This experiment adopts carrageenin to cause acute inflammation scale-model investigation antiinflammatory actions such as rat toes inflammatory swelling, and the result all has tangible antiinflammatory and refrigeration function to above-mentioned laboratory animal.
Therefore, anti-inflammatory medicine compositions of the present invention and the anti-inflammation formulation for preparing thus, has good antiinflammatory curative effect, compare with antibiotic medicine commonly used, few side effects, evident in efficacy, Chinese medicine composition of the present invention is pure Chinese medicine ingredients, scorching peaceful liquid preparation is the anti-inflammation formulation of pure Chinese medicine, does not contain other chemical antiinflammatory composition, takes for a long time to make human body produce drug resistance; The scorching peaceful preparation of the present invention is liquid preparation (oral liquid or syrup), compares with Chinese medicine antibiotic medicine commonly used, is more conducive to absorption of human body, and is rapid-action, taking convenience, and the each age group crowds such as old man, child that are suitable for take.
Above-described embodiment is described preferred implementation of the present invention; be not that scope of the present invention is limited; design under the prerequisite of spirit not breaking away from the present invention; various distortion and improvement that those of ordinary skills make technical scheme of the present invention all should fall in the definite protection domain of claims of the present invention.
Claims (3)
1. an anti-inflammatory medicine compositions is characterized in that: made by following parts by weight of Chinese traditional medicine raw material: Herba monochasmatis 1500-1568, Herba Commelinae 745-788, Herba Hedyotidis Diffusae 745-788;
This Chinese medicine composition is for having sugared type syrup, Sugarless type syrup or other oral liquid formulations;
It is 600-650 that the weight portion that sucrose adds in the sugared type syrup is arranged, the weight portion that sweeting agent described in the Sugarless type syrup adds is 0.5-5, and used sweeting agent is cyclamate, steviosin, acesulfame potassium, sucralose, alitame, novel compound sweeting agent, protein sugar, xylitol, dichloro chalcone derivative, oligosaccharide, erithritol, glycyrrhizin, Fructus Momordicae extracting solution or thaumati;
Take by weighing each raw medicinal material respectively by described proportioning, raw medicinal material is decocted with water twice, for the first time amount of water be medical material weight 6-15 doubly, for the second time amount of water be medical material weight 5-12 doubly, decocted 1.5 hours for the first time, decocted 1 hour for the second time, collecting decoction, filtration discards medicinal residues, and it is 1.0-1.10 that filtrate is concentrated into density, adds ethanol, making the alcohol amount of containing in the filtrate reach parts by weight is 50%-60%, stir, left standstill 10-14 hour, filter alcoholic solution, ethanol in the filtrate is reclaimed, last solution is the aqueous solution that does not contain alcohol, and it is 1.10-1.20 that the filtrate continuation of removing ethanol is concentrated into density, and it is standby to make extract;
Get the sucrose heating for dissolving of above-mentioned weight portion, add said extracted thing and antiseptic then, heated and boiled keeps little and boiled 20 minutes, is cooled to below 60 ℃, is settled to scale, continues to be cooled to 45-55 ℃, and packing has namely got sugared type syrup; Perhaps, get the said extracted thing and be heated to 55-65 ℃, add sweeting agent and the antiseptic heated and boiled of above-mentioned weight portion then, keep little and boiled 20 minutes, be cooled to below 60 ℃, be settled to scale, continue to be cooled to 45-55 ℃, packing namely gets the Sugarless type syrup; Perhaps, get the said extracted thing and add an amount of purified water heating dilution, add flavoring agent and antiseptic heated and boiled then, keep little and boiled 20 minutes, cooling is settled to scale below 60 ℃, continues to be cooled to 45-55 ℃, and packing namely gets oral liquid formulations;
Used antiseptic is sodium benzoate or potassium sorbate, and the mass volume ratio that addition accounts for the preparation total amount is 0.25%;
Used flavoring agent is essence and citric acid, the volume ratio that addition accounts for the preparation total amount respectively be 0.03% and the mass volume ratio of preparation total amount be 0.05%.
2. Chinese medicine composition according to claim 1 is characterized in that: made by following parts by weight of Chinese traditional medicine raw material: Herba monochasmatis 1550-1566, Herba Commelinae 750-785, Herba Hedyotidis Diffusae 750-785.
3. Chinese medicine composition according to claim 1 is characterized in that: made by following parts by weight of Chinese traditional medicine raw material: Herba monochasmatis 1562.5, Herba Commelinae 781.25, Herba Hedyotidis Diffusae 781.25.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110302145 CN102335272B (en) | 2011-09-28 | 2011-09-28 | Liquid preparation for diminishing inflammation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110302145 CN102335272B (en) | 2011-09-28 | 2011-09-28 | Liquid preparation for diminishing inflammation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102335272A CN102335272A (en) | 2012-02-01 |
| CN102335272B true CN102335272B (en) | 2013-09-04 |
Family
ID=45511372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110302145 Active CN102335272B (en) | 2011-09-28 | 2011-09-28 | Liquid preparation for diminishing inflammation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102335272B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660372A (en) * | 2005-01-31 | 2005-08-31 | 北京正大绿洲医药科技有限公司 | Oral drop pill in use for clearing sway heat and toxic material, relieving inflammation and dysentery, and preparation method |
| CN1686492A (en) * | 2005-04-11 | 2005-10-26 | 贵州宏奇药业有公司 | Antibicrobial anti inflammatory capsule and its preparation method |
| CN1730059A (en) * | 2005-06-10 | 2006-02-08 | 湖南麓山天然植物制药有限公司 | Yanning capsule and its preparation process |
-
2011
- 2011-09-28 CN CN 201110302145 patent/CN102335272B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1660372A (en) * | 2005-01-31 | 2005-08-31 | 北京正大绿洲医药科技有限公司 | Oral drop pill in use for clearing sway heat and toxic material, relieving inflammation and dysentery, and preparation method |
| CN1686492A (en) * | 2005-04-11 | 2005-10-26 | 贵州宏奇药业有公司 | Antibicrobial anti inflammatory capsule and its preparation method |
| CN1730059A (en) * | 2005-06-10 | 2006-02-08 | 湖南麓山天然植物制药有限公司 | Yanning capsule and its preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102335272A (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003260985B2 (en) | Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN103182023A (en) | Medicine for treating chronic pharyngitis and preparation method thereof | |
| CN103301400B (en) | A kind of Chinese medicine composition and preparation method for the treatment of chronic atrophic gastritis | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| ES2589131T3 (en) | Thyme extracts and their use | |
| CN102335272B (en) | Liquid preparation for diminishing inflammation and preparation method thereof | |
| CN102397458B (en) | Medicinal composition for treating senile pneumonia and preparation method thereof | |
| CN107638504B (en) | Heat-clearing cough-relieving oral liquid for children and preparation method thereof | |
| CN103169863B (en) | Medicament for treating constipation and preparation method thereof | |
| CN103520331B (en) | Traditional Chinese medicinal preparation for treating liver-stomach disharmony type chronic gastritis and preparation method for traditional Chinese medicinal preparation | |
| TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
| CN101518613B (en) | Chinese herbal decoction for treating cough | |
| CN105169149A (en) | Traditional Chinese medicine composition for treating pyrophlegm stasis accumulation type thyroid cancer, preparation method and application | |
| CN104225344A (en) | Chinese herbal preparation for treating chronic nephropyelitis and preparation method thereof | |
| CN111419894A (en) | A kind of pharmaceutical composition for lowering uric acid and preparation method thereof | |
| CN102247470B (en) | A kind of Chinese medicine composition preventing and treating infant upper respiratory tract infection | |
| CN104013815A (en) | Traditional Chinese medicine for treating recurrent oral ulcer due to deficiency of yin and excess of heat and preparation method of traditional Chinese medicine | |
| CN103550528A (en) | Chinese herbal preparation for treating stomach-Yin deficient chronic gastritis and preparation method thereof | |
| CN102793736A (en) | Buccal tablet with removing throat heat and promoting diuresis | |
| CN100345561C (en) | Chinese medicinal preparation for treating gallstone and its preparation method | |
| CN103721061A (en) | External traditional Chinese medicine preparation for treating chronic nasosinusitis and preparation method thereof | |
| KR20170103602A (en) | Composition of the extract of combined herb including the peel extract of mandarin fructus for preventing and treating constipation | |
| CN105288202A (en) | Pharmaceutical composition for curing infantile cough | |
| CN104707124A (en) | Traditional Chinese medicine preparation for treating chronic endometritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |